Cubist Hopes For A Blockbuster Antibiotic With In Acquisition Of Calixa
This article was originally published in The Pink Sheet Daily
Executive SummaryCubist pays $92.5 million upfront for a private biotech and its lead programs, hoping to find a complementary product for Cubicin.
You may also be interested in...
Earn-outs are more frequent in biotech M&A deals these days, but private investors also are becoming more savvy in terms of tracking earn-outs and which ones are more likely than others to pay off.